IRWDIRONWOOD PHARMACEUTICALS INC同业对比
IRONWOOD PHARMACEUTICALS INC 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IRWD本股 | $672M#8 | 5.1x#2 | — | 2.3x#3 | -15.7%#9 | 2629.5%#1 | 33.3%#2 | — | 42.6%#2 | — | 217.6%#3 | — |
| GYRE | $743M#1 | — | 6.9x#10 | 6.4x#5 | 10.2%#7 | -44.8%#13 | 9.9%#4 | 9.2%#5 | 12.0%#3 | 3#3 | -10.5%#12 | 6.1%#1 |
| NVCT | $718M#2 | — | 79.1x#12 | — | — | -39.2%#12 | — | -291.1%#12 | — | — | 253.7%#1 | — |
| COLL | $712M#3 | 17.2x#5 | 2.3x#4 | 0.9x#1 | 23.6%#6 | -8.7%#10 | 23.0%#3 | 20.2%#4 | 62.0%#1 | 4#1 | -37.4%#15 | — |
| MNPR | $700M#4 | — | 5.4x#9 | — | — | 12.0%#8 | — | -10.5%#8 | — | — | 116.2%#4 | — |
| CBIO | $699M#5 | — | 4.3x#8 | 64.4x#10 | — | 306.4%#3 | -1407.5%#11 | 0.1%#6 | — | — | 54.0%#8 | — |
| ZVRA | $692M#6 | 12.5x#4 | 3.2x#7 | 6.5x#6 | 350.9%#2 | 178.9%#4 | -59.1%#6 | 38.2%#1 | — | — | 61.3%#7 | — |
| NGNE | $672M#7 | — | 3.1x#6 | — | -100.0%#13 | -20.2%#11 | — | -41.6%#11 | — | — | 89.6%#6 | — |
| VSTM | $665M#9 | — | 13.3x#11 | 21.5x#9 | 209.1%#4 | -60.3%#14 | -550.3%#10 | -419.1%#13 | — | — | -25.3%#13 | — |
| PHAT | $659M#10 | — | — | 3.8x#4 | 216.9%#3 | 33.8%#7 | -91.4%#7 | — | — | 4#1 | -28.9%#14 | — |
| ALT | $628M#11 | — | 1.3x#2 | 15324.2x#12 | 105.0%#5 | 7.3%#9 | -230461.0%#13 | -18.6%#9 | -21.1%#5 | — | -10.0%#11 | — |
| FBIOP | — | 6.7x#3 | — | — | 9.7%#8 | 76.2%#5 | -111.0%#8 | 22.5%#3 | — | — | 110.5%#5 | — |
| AQST | $605M#12 | — | — | 13.6x#8 | -22.6%#10 | -89.8%#15 | -159.5%#9 | — | — | — | -6.2%#10 | — |
| CRMD | $604M#13 | 3.6x#1 | 1.3x#1 | 1.9x#2 | 617.0%#1 | 1009.4%#2 | 48.2%#1 | 35.4%#2 | — | — | -38.7%#16 | — |
| STTK | $599M#14 | — | 2.8x#5 | 599.2x#11 | -82.5%#12 | 35.3%#6 | -5150.8%#12 | -23.1%#10 | — | — | 233.5%#2 | — |
| CTMX | $588M#15 | — | 1.9x#3 | 7.7x#7 | -44.8%#11 | -154.5%#16 | -29.3%#5 | -5.7%#7 | -7.8%#4 | — | 35.7%#9 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-16。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议